Aptose Biosciences Inc (APS) Receives “Outperform” Rating from Royal Bank Of Canada
Aptose Biosciences Inc (TSE:APS)‘s stock had its “outperform” rating restated by analysts at Royal Bank Of Canada in a research report issued to clients and investors on Friday, StockTargetPrices.com reports. They presently have a C$24.00 price target on the stock.
Aptose Biosciences (TSE:APS) traded down 4.69% on Friday, reaching $3.05. 24,690 shares of the company’s stock were exchanged. Aptose Biosciences has a 1-year low of $2.51 and a 1-year high of $8.33. The stock’s 50 day moving average price is $2.90 and its 200 day moving average price is $3.21. The firm’s market capitalization is $39.32 million.
About Aptose Biosciences
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/aptose-biosciences-inc-aps-receives-outperform-rating-from-royal-bank-of-canada-2.html
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.